Glucagon-like peptide-1 (GLP-1) agonists offer significant promise to patients with obesity, and newer drugs can help them shed more than one-quarter of their body weight in some cases. But many adults in the US who have this chronic disease aren’t staying on GLP-1s long enough to see a “clinically meaningful health benefit,” a recent study from Blue Health Intelligence (BHI) and the Blue Cross Blue Shield Association found.
Some 58% of patients discontinue these medications within 12 weeks, according to the findings, which are based on data from more than 170,000 commercial health plan members dating back to 2014. Research has shown patients taking GLP-1s should “complete at least 12 weeks of continuous treatment” in order to see clinically meaningful results, i.e., at least a 5% weight loss, according to the study.
Most patients in the study (79%) were female, and 42% lived in the Northeast. Over half of the patients received their prescription from a primary care provider, and nearly two-thirds were categorized as “low” for social vulnerability, which is a metric that assesses a community’s vulnerability through external factors like sociodemographic status.
The study states barriers like cost, transportation, and language as factors may inhibit some patients’ ability to continue GLP-1 medications. Ongoing shortages of GLP-1 drugs may also hinder access.
A separate paper recently published in JAMA found 26% of patients discontinued GLP-1s within three months, while about 37% stopped treatment within a year.
Keep reading here.—CV
|